MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a Keynote lecture at the World Conference on Regenerative Medicine being held in Leipzig, Germany October 23-25th. The Conference is considered one of the world's largest and most influential events in stem cells and regenerative medicine, and provides a platform that brings scientists with an academic, clinical and industrial background together. Dr. Lanzas Lecture, entitled ES and iPS Cells Moving into the Clinic, will take place at 9:00 a.m. at the Congress Center Leipzig.

The World Conference will, as in past years, encompass a broad range of topics in regenerative medicine from biomaterials to biomarkers as well as regulation and stem cell technologies. The organizers expect more than 1,000 attendees and hundreds of papers with ground-breaking scientific insights and new results. Furthermore, the conference will host a large exhibition where international researchers and biotechnology companies can demonstrate the reach of current technologys translation and the implementation of research in products. In addition to Dr. Lanzas Keynote Lecture, the Conference will include presentations on cell and immunotherapy, stem cells, cell and tissue engineering, biomaterials and tissue interaction, models of regeneration, molecular mechanisms of regeneration, diagnostic and imaging of regeneration, and regulatory affairs.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, the relevance and applicability of clinical trials in animals to studying the effect of products in humans, future growth in animal and human research and development programs, potential new applications of and expanded indications covering our technology, the effects of donorless sources of stem cells on potency and the risk of communicable diseases in the manufacturing context, the existence and size of potential or existing market opportunities for the company, the effect of the companys products on the medical needs and quality of life of pets, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for and limited sources of future capital, failures or delays in obtaining regulatory approval of products, risks inherent in the development and commercialization of potential products, reliance on new and unproven technology in the development of products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the Quarterly Report on Form 10-Q for the three months ended June 30, 2013. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Go here to see the original:

ACT’s Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine